Abstract:Boceprevir is an HCV NSP3 inhibitor that was explored as a repurposed drug for COVID-19. It inhibits the SARSCoV-2 main protease (MPro) and contains an alpha-ketoamide warhead, a P1 beta-cyclobutylalanyl moiety, a P2 dimethylcyclopropylproline, a P3 tert-butylglycine, and a P4 N-terminal tert-butylcarbamide. By introducing modifications at all four positions, we synthesized 20 boceprevir-based MPro inhibitors including PF-07321332 and characterized their MPro inhibition potency in test tubes (in vitro) and 293T cells (in cellulo). Crystal structures of MPro bound with 10 inhibitors and cytotoxicity and antiviral potency of 4 inhibitors were characterized as well. Replacing the P1 site with a beta-(S-2-oxopyrrolidin-3-yl)-alanyl (Opal) residue and the warhead with an aldehyde leads to high in vitro potency. The original moieties at P2, P3 and the P4 N-terminal cap positions in boceprevir are better than other tested chemical moieties for high in vitro potency. In crystal structures, all inhibitors form a covalent adduct with the MPro active site cysteine. The P1 Opal residue, P2 dimethylcyclopropylproline and P4 N-terminal tert-butylcarbamide make strong hydrophobic interactions with MPro, explaining high in vitro potency of inhibitors that contain these moieties. A unique observation was made with an inhibitor that contains a P4 N-terminal isovaleramide. In its MPro complex structure, the P4 N-terminal isovaleramide is tucked deep in a small pocket of MPro that originally recognizes a P4 alanine side chain in a substrate. Although all inhibitors show high in vitro potency, they have drastically different in cellulo potency to inhibit ectopically expressed MPro in human 293T cells. In general, inhibitors with a P4 N-terminal carbamide or amide have low in cellulo potency. This trend is reversed when the P4 N-terminal cap is changed to a carbamate. The installation of a P3 O-tert-butyl-threonine improves in cellulo potency. Three molecules that contain a P4 N-terminal carbamate were advanced to cytotoxicity tests on 293T cells and antiviral potency tests on three SARS-CoV-2 variants. They all have relatively low cytotoxicity and high antiviral potency with EC50 values around 1 mu M. A control compound with a nitrile warhead and a P4 N-terminal amide has undetectable antiviral potency. Based on all observations, we conclude that a P4 N-terminal carbamate in a boceprevir derivative is key for high antiviral potency against SARS-CoV-2.

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Structural Basis for coronaviral main proteases Inhibition by a 3CL Protease Inhibitor- GC376

Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation

Structural Basis for Coronaviral Main Proteases Inhibition by the 3clpro Inhibitor GC376.

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model

A Systematic Exploration of Boceprevir-Based Main Protease Inhibitors As SARS-CoV-2 Antivirals.

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3Clpro

Structural basis for the inhibition of coronaviral main proteases by PF-00835231

Discovery of 3-Oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin Derivatives As SARS-CoV-2 Main Protease Inhibitors Through Virtual Screening and Biological Evaluation.

Discovery of potential inhibitors targeting SARS-CoV-2 Mpro

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development